Atria Investments Inc Decreases Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Atria Investments Inc lessened its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 19.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,774 shares of the company’s stock after selling 3,360 shares during the period. Atria Investments Inc’s holdings in Centessa Pharmaceuticals were worth $231,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its holdings in shares of Centessa Pharmaceuticals by 88.1% during the third quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock valued at $4,237,000 after buying an additional 124,075 shares during the last quarter. FMR LLC grew its stake in Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock valued at $46,635,000 after purchasing an additional 129,300 shares during the last quarter. Ally Bridge Group NY LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at about $4,951,000. Suvretta Capital Management LLC purchased a new position in shares of Centessa Pharmaceuticals in the third quarter worth about $1,119,000. Finally, Walleye Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $187,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insiders Place Their Bets

In other news, insider Karen M. Anderson sold 6,471 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $109,101.06. Following the sale, the insider now owns 54,322 shares of the company’s stock, valued at approximately $915,868.92. The trade was a 10.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the transaction, the insider now directly owns 183,266 shares in the company, valued at approximately $3,122,852.64. This trade represents a 5.17 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 247,168 shares of company stock valued at $4,138,928. Insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $16.51 on Wednesday. The firm has a 50-day simple moving average of $16.45 and a 200-day simple moving average of $16.36. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -10.79 and a beta of 1.54. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.